References
- SchaferAIThe hypercoagulable statesAnn Intern Med19851028148183158262
- FradeLJGde la CalleHAlavaIDiabetes as a hypercoagulable state: its relationship with fibrin fragments and vascular damageThromb Res1987475335403118498
- NomuraSOzakiYIkedaYFunction and role of microparticles in various clinical settingsThromb Res200812382318667228
- CominaciniLPasiniAFGarbinUElevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic controlDiabetologia199538112211248591829
- LimYCSnappKKansasGSImportant contributions of P-selectin glycoprotein ligand-1-mediated secondary capture to human monocyte adhesion to P-selectin, E-selectin, and TNF-α-activated endothelium under flow in vitroJ Immunol1998161250125089725249
- TschopeDEsserJSchwippertBLarge platelets circulate in an activated state in diabetesSemin Thromb Haemost199117433439
- NomuraSShouzuAOmotoSSignificance of chemokines and activated platelets in patients with diabetesClin Exp Immunol200012143744310971508
- RodriguezBLLauNBurchfielCMGlucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart ProgramDiabetes Care1999221262126510480768
- CoutinhoMGersteinHCWangYThe relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 yearsDiabetes Care19992223324010333939
- The DECODE study group on behalf of the Europearn Diabetes Epidemiology GroupGlucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Diabetes Epidemiology: collaborative analysis of diagnostic criteria in EuropeLancet199935461762110466661
- NakagamiTHyperglycaemia and mortality from all cause and from cardiovascular disease in five populations of Asian originDiabetologia20044738539414985967
- ChiassonJLJosseRGGomisRAcarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trialLancet20023592072207712086760
- ChiassonJLJosseRGGomisRAcarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trialJAMA200329048649412876091
- HanefieldMChiassonJLKoehlerCAcarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose toleranceStroke2004351073107815073402
- HanefeldMCagatayMPetrowitschTAcarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studiesEur Heart J200425101614683737
- AhrHJBobergMBrendelEKrauseHPSteinkeWPharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and manArzneimittelforschung1997477347459239452
- OsumiKOzekiYSaitoSDevelopment and assessment of enzyme immunoassay for platelet-derived microparticlesThromb Haemost20018532633011246556
- NomuraSUehataSSaitoSEnzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndromeThromb Haemost20038950651212624635
- NomuraSShouzuATaomotoKAssessment of an ELISA kit for platelet-derived microparticles by joint research at many institutes I JapanJ Atheroscler Thromb20091687888720032575
- SimsPJFaioniEMWiedmerTComplement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activityJ Biol Chem198826318205182122848029
- NomuraSSuzukiMKatsuraKPlatelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitusAtherosclerosis19951162352407575778
- NomuraSTandonNNNakamuraTHigh-shear-stress- induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cellsAtherosclerosis200115827728711583705
- NomuraSShouzuAOmotoSEffect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetesThromb Haemost1998803883929759615
- NomuraSInamiNIwasakaTPlatelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamolePlatelets20041516717215203718
- NomuraSTakahashiNInamiNProbucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetesAtherosclerosis200417432933515136063
- KurowskaEMNitric oxide therapies in vascular diseasesCurr Pharm Des2002815516611812265
- OuchiNKiharaSAritaYNovel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein, adiponectinCirculation19991002473247610604883
- ArakawaMEbatoCMitaTMiglitol suppresses the post-prandial increase in interleukin 6 and enhances active glucagons-like peptide secretion in viscerally obese subjectsMetabolism Clin Exp20085712991306
- YokoyamaHKannoSIshimuraINodeKMiglitol increases adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitusMetabolism Clin Exp20085614581463
- OuchiNKiharaSAritaYAdiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappa B signaling through a cAMP-dependent pathwayCirculation20001021296130110982546
- HottaKFunahashiTAritaYPlasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetes patientsArtherioscler Thromb Vasc Biol20002015951599
- ShimabukuroMHigaNAsahiTHypoadiponectinemia is closely linked to endothelial dysfunction in manJ Clin Endocrinol Metab2003883236324012843170
- ChenHMontagnaniMFunahashiTAdiponectin stimulates production of nitric oxide in vascular endothelial cellsJ Biol Chem2003278450214502612944390
- HattoriYSuzukiMHattoriSGlobular adiponectin upregulates nitric oxide production in vascular endothelial cellsDiabetologia2003461543154914551684
- NomuraSShouzuAOmotoSCorrelation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitusThromb Res2008122394517920663
- WangYLamKSChanLPost-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complexJ Biol Chem2006281163911640016621799
- FülöpNMarchaseRBChathamJCRole of protein O-linked N-acetyl-glucosamine in mediating cell function and survival in the cardiovascular systemCardiovasc Res20077328829716970929
- FülöpNMasonMMDuttaKImpact of Type 2 diabetes and aging on cardiomyocyte function and O-linked N-acetylglucosamine levels in the heartAm J Physiol Cell Physiol2007292C1370C137817135297
- OchiaiHOokaHShidaCAcarbose treatment increases serum total adiponectin levels in patients with type 2 diabetesEndocr J20085554955618480556
- KnopFKVilsbollTLarsenSMadsbadSHolstJJKrarupTNo hypoglycemia after subcutaneous administration of glucagons-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitisDiabetes Care2003262581258712941722
- PocaiACarringtonPEAdamsJRGlucagon-like peptide 1/glucagons receptor dual agonism reverses obesity in miceDiabetes2009582258226619602537
- KimVhung leTHosakaTYoshidaMExendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expressionBiochem Biophys Res Commun200939061361819850014